CINECA IRIS Institutional Research Information System

FALCONE, ALFREDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 47.564
EU - Europa 16.797
AS - Asia 7.866
AF - Africa 477
SA - Sud America 59
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 18
AN - Antartide 1
Totale 72.832
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 46.275
IT - Italia 6.271
CN - Cina 3.574
SE - Svezia 2.805
BG - Bulgaria 2.024
SG - Singapore 1.828
DE - Germania 1.433
CA - Canada 1.271
UA - Ucraina 1.103
TR - Turchia 977
VN - Vietnam 865
GB - Regno Unito 796
FI - Finlandia 685
CH - Svizzera 533
RU - Federazione Russa 400
FR - Francia 291
CI - Costa d'Avorio 278
HK - Hong Kong 243
IN - India 183
AT - Austria 123
BE - Belgio 83
SN - Senegal 79
NG - Nigeria 61
NL - Olanda 58
BR - Brasile 44
JP - Giappone 43
BJ - Benin 41
AU - Australia 34
ES - Italia 31
KR - Corea 29
PK - Pakistan 29
PL - Polonia 28
GR - Grecia 18
CZ - Repubblica Ceca 17
EU - Europa 17
IE - Irlanda 16
NZ - Nuova Zelanda 16
TW - Taiwan 16
IL - Israele 12
IR - Iran 12
RO - Romania 12
DK - Danimarca 11
MX - Messico 11
MY - Malesia 11
HU - Ungheria 10
LU - Lussemburgo 10
NO - Norvegia 9
ID - Indonesia 8
EG - Egitto 7
PT - Portogallo 7
LT - Lituania 6
PH - Filippine 6
SA - Arabia Saudita 6
AR - Argentina 5
CR - Costa Rica 5
NP - Nepal 5
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
KZ - Kazakistan 3
MG - Madagascar 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BD - Bangladesh 2
DZ - Algeria 2
EC - Ecuador 2
LV - Lettonia 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
BS - Bahamas 1
CO - Colombia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HR - Croazia 1
IM - Isola di Man 1
IQ - Iraq 1
KH - Cambogia 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
RE - Reunion 1
RS - Serbia 1
SI - Slovenia 1
SM - San Marino 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 72.832
Salva come PNG Salva come JPEG
Città #
Woodbridge 7.970
Ann Arbor 5.026
Houston 4.540
Fairfield 4.067
Chandler 3.265
Milan 2.761
Ashburn 2.196
Santa Clara 2.075
Sofia 2.022
Seattle 1.788
Jacksonville 1.643
Wilmington 1.593
Cambridge 1.554
Ottawa 1.213
New York 1.195
Beijing 1.122
Singapore 1.017
Boardman 914
Princeton 852
Lawrence 788
Nanjing 703
Izmir 701
Medford 671
Serra 565
Bern 520
Dearborn 448
Des Moines 416
Dong Ket 338
Jüchen 299
Nanchang 290
Abidjan 278
Rome 271
Istanbul 259
Düsseldorf 244
San Diego 220
Florence 216
Hong Kong 216
Pisa 208
Redwood City 203
Boulder 172
London 162
Shenyang 151
Kunming 145
Ogden 132
Los Angeles 123
Hebei 122
Vienna 121
Changsha 113
Lancaster 105
Bremen 96
Norwalk 92
Tianjin 92
Frankfurt am Main 91
Jiaxing 88
Shanghai 81
Hefei 80
Dakar 79
Washington 76
Brussels 71
Guangzhou 61
Lagos 59
Fuzhou 57
Auburn Hills 52
Pune 52
Seacroft 52
Orange 50
Hangzhou 49
Phoenix 49
Chicago 44
Jinan 43
Cotonou 41
Grafing 41
Dallas 37
Falls Church 33
Detroit 31
Kent 31
Marseille 29
Positano 29
Verona 29
Helsinki 26
Toronto 25
Lanzhou 23
Lappeenranta 21
Warsaw 21
Chengdu 19
Nürnberg 19
Multan 18
Paris 18
San Francisco 18
Wuhan 18
Groningen 16
Hyderabad 16
Quanzhou 16
Bologna 15
Changchun 15
Edinburgh 15
Indiana 15
Can Tho 14
Walnut 14
Lugo 13
Totale 58.103
Salva come PNG Salva come JPEG
Nome #
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity 310
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 249
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 197
Zebrafish embryos as avatar of patients with pancreatic cancer: preliminary results of validation a new model toward personalized medicine 188
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach 186
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 180
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 169
Prognostic relevance of lymph node metastases and adjuvant treatment for patients with invasive intraductal papillary mucinous (IPMNs) of the pancreas 168
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 167
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 165
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 160
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer 159
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy 158
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 158
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 158
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 158
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region 157
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 157
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 156
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group 155
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation 155
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 153
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer 153
FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis 152
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 151
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 151
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine 150
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study 148
The effect of bevacizumab plus chemotherapy on the immunological profile of advanced colorectal cancer patients 148
Optimal approach to potentially resectable liver metastases from colorectal cancer 148
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 148
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 146
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 146
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study 145
A PILOT STUDY OF A DAY ONE AND EIGHT EVERY THREE WEEKS ADMINISTRATION OF DOCETAXEL IN METASTATIC CANCER PATIENTS 144
A phase II study of oral doxifluridine in elderly patients with advanced non small cell lung cancer 143
Cancer pharmacogenomics: germline DNA, tumor DNA, or both? 143
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 143
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) 143
Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? 143
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO) 142
Genetic analysis of cytidine deaminase (CDA) for the prediction of response to chemotherapy and survival in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine 142
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) 142
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 141
TAS-102 for the treatment of metastatic colorectal cancer 141
Preliminary experience with Xenotransplantation of pancreatic cancer samples in zebrafish embryos: towards personalized medicine 141
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer 140
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 140
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 140
Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan-and/or oxaliplatin-based chemotherapy 139
Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small cell lung cancer 138
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly 138
5-fluorouracil enhances azidothymidine cytotoxicity. In vitro, in vivo and biochemical studies 137
Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study 137
Cisplatin plus gemcitabine as adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC): a phase II tolerability study 137
Palliative treatment of unresectable metastatic colorectal cancer 137
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 137
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC) 137
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role 137
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 136
A PHASE ii TRIAL OF FIXED-DOSE RATE GEMCITABINE PLUS CAPECITABINE IN METASTATIC/ADVANCED BILIARY TRACT CANCER PATIENTS. 135
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 135
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 135
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 134
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer 134
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib 133
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 133
Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer 133
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 133
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 133
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 133
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 133
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 132
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 132
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 132
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 132
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 131
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 131
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 131
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 130
Economic evaluation of the cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin (XP) vs. 5-FU/cisplatin (FP) regimens in an Italian setting 130
A phase II pilot study of sequential chemo-immunotherapy with capecitabina+ interferon α2A (IFN) followed by interleukina-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC): on behalf of the Gruppo Oncologico Nord Ovest (G.O.N.O.) 130
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 130
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. 130
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 130
Differential effects of benzylacyclouridine on the toxicity and therapeutic effects of azidothymidine in mice 129
Nuclear factor kB (NF-kB) may predict efficacy of cetuximab therapy in EGFR-positive colorectal cancer 129
null 129
Radium 223 dichloride: A multidisciplinary approach to metastatic castration-resistant prostate cancer 129
Feasibility and efficacy of 223Ra-dichloride (223Ra) to treat bone metastases in patients (pts) with castration resistant prostate cancer (mCRPC) 129
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 129
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 128
A randomised phase II study of cetuximab plus gemcitabine/cisplatin combination in advanced pancreatic cancer (APC) 128
The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD 128
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 128
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 128
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 128
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients 127
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients? 127
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 127
Totale 14.515
Salva come PNG Salva come JPEG
Categoria #
all - tutte 198.529
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 198.529
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.921 0 0 0 0 0 1.277 1.365 907 1.338 758 1.015 261
2020/20216.561 592 389 348 274 691 511 478 528 673 530 384 1.163
2021/20227.610 90 506 190 432 1.488 1.237 141 305 339 265 474 2.143
2022/20238.514 1.149 935 504 790 1.105 1.171 46 682 1.405 52 593 82
2023/20248.893 1.374 1.213 1.178 711 1.395 1.348 217 259 154 134 198 712
2024/20255.047 111 887 274 1.049 1.521 1.205 0 0 0 0 0 0
Totale 73.787